Clinical Trials Logo

Chronic Hepatitis D Infection clinical trials

View clinical trials related to Chronic Hepatitis D Infection.

Filter by:
  • None
  • Page 1

NCT ID: NCT06248580 Recruiting - Clinical trials for Hepatocellular Carcinoma

Find HDV and Determine Its Status in Turkey

SITUHDVATION
Start date: March 11, 2024
Phase:
Study type: Observational [Patient Registry]

The aim of these study to determine the prevalence of hepatitis Delta virus (HDV) infections and the prognosis of HDV patients in Turkey's southeast. The investigators intend to arrange training sessions for 250 family physicians in Diyarbakir, Batman, Mardin, and Sanliurfa in order to determine those goals. The investigators will talk about diagnosing hepatitis B virus (HBV), HDV, hepatitis C virus (HCV), and Human Immunodeficiency virus (HIV) infections during these events. To ensure that patients with simultaneous HDV infection are evaluated for HIV/HCV and to detect liver fibrosis with a non-invasive method.

NCT ID: NCT05827146 Completed - Clinical trials for Chronic Hepatitis D Infection

Study of Hepalatide in Chronic Hepatitis D(CHD) Patients

Start date: October 7, 2023
Phase: Phase 2
Study type: Interventional

A phase 2a clinical Study of Hepalatide for Injection in Subjects with Chronic Hepatitis D

NCT ID: NCT05765344 Recruiting - Clinical trials for Chronic Hepatitis D Infection

Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function

Start date: March 15, 2023
Phase: Phase 1
Study type: Interventional

The goals of this study are to measure the amount of bulevirtide (BLV) that gets into the blood stream and how long it takes to get rid of it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with normal and impaired hepatic (liver) function.

NCT ID: NCT05760300 Recruiting - Clinical trials for Chronic Hepatitis D Infection

A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function

Start date: March 15, 2023
Phase: Phase 1
Study type: Interventional

The goals of this study are to compare the amount of study drug, bulevirtide (BLV), that gets into the bloodstream and how long it takes for the body to eliminate it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with normal or impaired renal (kidney) function.

NCT ID: NCT05718700 Recruiting - Clinical trials for Chronic Hepatitis D Infection

Study of Bulevirtide in Participants With Chronic Hepatitis D Infection

Start date: February 7, 2023
Phase:
Study type: Observational [Patient Registry]

The main goal of this study is to collect post marketing data from patients with chronic hepatitis D virus (HDV) infection who are treated with bulevirtide to describe the long-term effects of bulevirtide treatment and evaluate the safety of participants treated with bulevirtide.

NCT ID: NCT04638439 Recruiting - Clinical trials for Chronic Hepatitis B Infection

The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection

Start date: December 2021
Phase: Phase 1
Study type: Interventional

Primary objective: To evaluate the safety and tolerability of sequential administration of P1101 and anti-PD1 in patient with chronic hepatitis B or D infection Secondary objectives: 1. To explore HBsAg loss and kinetics during the study period 2. To assess the anti-viral effect during the study period 3. To evaluate the rate of ALT normalization

NCT ID: NCT02637999 Completed - Clinical trials for Chronic Hepatitis D Infection

Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection

Start date: February 13, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Randomized open-label substudy of daily Myrcludex B (MXB) plus pegylated interferon-alpha-2a (PEG-INF-a) in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B virus (HBV) co-infected with hepatitis delta virus (HDV).

NCT ID: NCT02430194 Completed - Clinical trials for Chronic Hepatitis D Infection

Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)

LOWR-2
Start date: December 2014
Phase: Phase 2
Study type: Interventional

An Open-label, Dose-ranging Study to Evaluate the Safety and Efficacy of Lonafarnib with Ritonavir Boosting +/- Peginterferon alfa-2a in Patients Chronically Infected with Delta Hepatitis (HDV) (LOWR-2).

NCT ID: NCT02430181 Completed - Clinical trials for Chronic Hepatitis D Infection

Lonafarnib With and Without Ritonavir in HDV (LOWR-1)

LOWR-1
Start date: November 2014
Phase: Phase 2
Study type: Interventional

To Evaluate the Safety and Efficacy of Lonafarnib with and without Ritonavir Boosting in Adults With Genotype 1 Chronic Hepatitis D Virus (HDV) Infection (LOWR-1).